Clinical Overview of Diphyllobothriid tapeworm Infection

Key points

  • Diphyllobothriid tapeworm infections are treatable with medication.
  • Treatment is safe and effective.

Treatment and recovery

Drug

Dosage

Directions

Praziquantel*

Adults and children: 5 – 10 mg/kg orally in a single-dose therapy.

Take with liquids during a meal.

Niclosamide**

Adults: 2 gm orally, once.
Children: 50mg/kg (max 2 gm) orally, once.

Chew thoroughly or crush and swallow with a small amount of water.

Neither medication is FDA approved for this indication.

*Oral praziquantel is available for human use in the United States.
**NOT available for human use in the United States; used in other countries to treat various parasitic infections.

Care precautions

Praziquantel

Treatment in Pregnancy

Praziquantel is a pregnancy category B drug. There are no adequate and well-controlled studies in pregnant women. However, the available evidence suggests no difference in adverse birth outcomes in the children of women who were accidentally treated with praziquantel during mass drug administration (MDA) campaigns compared with those who were not. In MDA campaigns for which the World Health Organization (WHO) has determined that the benefit of treatment outweighs the risk, WHO encourages the use of praziquantel in any stage of pregnancy. For individual patients in clinical settings, healthcare providers should consider the risk of treatment in infected pregnant women with the risk of disease progression in the absence of treatment.

Pregnancy Category B: Either animal-reproduction studies have not demonstrated a fetal risk plus there are no controlled studies in pregnant women, or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the first trimester (and there is no evidence of a risk in later trimesters).

Treatment During Lactation

Praziquantel is excreted in low concentrations in breast milk. According to WHO guidelines for MDA campaigns, the use of praziquantel during lactation is encouraged. For individual patients in clinical settings, healthcare providers should consider the risk of treatment in infected breastfeeding women with the risk of disease progression in the absence of treatment.

Treatment in Pediatric Patients

The safety of praziquantel in children aged less than 4 years has not been established. WHO now recommends treating children at least 2 years of age with praziquantel during MDA campaigns for schistosomiasis control, citing evidence that praziquantel is safe in this age group. For individual patients in clinical settings, healthcare providers should consider the risk of treatment in children younger than 4 years old with the risk of disease progression in the absence of treatment.

Niclosamide

Treatment in Pregnancy

Niclosamide is a pregnancy category B drug. Data on the use of niclosamide in pregnant women are limited. Niclosamide is minimally absorbed from the gastrointestinal tract. Healthcare providers should consider the risk of treatment in infected pregnant women with the potential risk to the fetus in the absence of treatment.

Pregnancy Category B: Either animal-reproduction studies have not demonstrated a fetal risk plus there are no controlled studies in pregnant women, or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the first trimester (and there is no evidence of a risk in later trimesters).

Treatment During Lactation

It is not known whether niclosamide is excreted in breast milk, although niclosamide is minimally absorbed from the gastrointestinal tract. The World Health Organization (WHO) classifies niclosamide as compatible with breastfeeding, although there are limited data on the use of niclosamide during lactation.

Treatment in Pediatric Patients

The safety of niclosamide in children has not been established, although niclosamide is minimally absorbed from the gastrointestinal tract. Available evidence suggests that the safety profiles are comparable in children 2 years or older and adults.